Publications by authors named "J P Capron"
Article Synopsis
- The study investigates the differences between cerebral amyloid angiopathy-related inflammation (CAA-RI) and biopsy-positive primary angiitis of the CNS (BP-PACNS), focusing on their clinical and radiologic presentations as well as relapse rates.
- It included 104 patients with CAA-RI and 52 with BP-PACNS, revealing that CAA-RI tends to show more white matter lesions and hemorrhagic features, while BP-PACNS is associated more with headaches and motor deficits.
- The results indicate significant differences in features between the two conditions, suggesting that they may require different diagnostic approaches and could have varying outcomes in terms of recurrence.
Article Synopsis
- The study aimed to determine which clinical and radiological features are linked to positive CNS biopsies in patients suspected of having primary angiitis of the central nervous system (PACNS).
- Out of 200 patients with PACNS, 100 underwent biopsies, with 61% returning positive; factors like being female, having seizures or cognitive impairment, and specific imaging findings were associated with positive results.
- The findings suggest that certain characteristics can aid doctors in deciding whether or not to perform a CNS biopsy for suspected PACNS cases.
Unlabelled: Recent studies suggest that sleep disorders are present in two-thirds of patients with autoimmune encephalitis. In anti-Ma2 encephalitis, hypersomnia appears to be frequent. However, only few cases of type 1 narcolepsy have been reported to date with anti-Ma2 encephalitis.
View Article and Find Full Text PDFObjectives: We aimed to quantify patient preferences for efficacy, safety and convenience features of atopic dermatitis (AD) treatments.
Design And Setting: Online discrete choice experiment survey.
Participants: Adults in the UK, France and Spain who had used AD treatments during the past 2 years.
Article Synopsis
- The study used indirect treatment comparison to evaluate the effectiveness of baricitinib vs. dupilumab in adult patients with moderate-to-severe atopic dermatitis, focusing on approved doses.
- At weeks 4 and 16, baricitinib showed a greater improvement in itch scores than dupilumab, particularly in patients using it as monotherapy or alongside topical corticosteroids, though differences weren't as pronounced at week 16.
- Overall, baricitinib may provide faster relief from itching while maintaining similar levels of overall skin improvement and quality of life compared to dupilumab.